SynthesisParasite (Paris, France)2025
Systematic review and meta-analysis of the global prevalence and infection risk factors of Trichomonas vaginalis.
Synthesis in Parasite (Paris, France), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Five Clinically Relevant Genital Microorganisms Among Women in South America, 2014-2024: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2026Pooled it
- Machine Learning Classification Models for the Design of Novel Nitroimidazole Derivatives with Anti-ACS omega · 2026Article
- Old but gold: an historical perspective of wet mount microscopy and its current role for the diagnosis of vaginitis.Frontiers in reproductive health · 2026Review
- Chromosome-level genome assembly of Trichomonas vaginalis strain IR-78 (ATCC 50138).Scientific data · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Trichomoniasis is a globally prevalent sexually transmitted disease; however, comprehensive data on its global prevalence and incidence are relatively limited. In this study, we systematically retrieved relevant articles from PubMed, Google Scholar, Scopus, Ovid-Medline, and Web of Science to analyze the prevalence of Trichomonas vaginalis and its association with various infection risk factors. Among 5,437 publications released between 1992 and 2023, 425 articles focusing on the epidemiology of T. vaginalis were identified. The results revealed a global prevalence rate of T. vaginalis of 8% (95% CI: 7%-10%), with country-specific rates ranging from 1% to 35%. The prevalence of T. vaginalis was significantly higher in the behavioral subgroups, including smoking, drug use, and not using condoms, compared to the non-infection group, with a pooled odds ratio (OR) of 1.67 (95% CI: 1.39-2.0). Furthermore, the prevalence of T. vaginalis was significantly higher in the group with other sexually transmitted infections (STIs), including HIV, HSV, and Chlamydia infection compared to the non-infection group, with a pooled OR of 2.01 (95% CI: 1.48-2.72). Finally, socioeconomic factors such as being unmarried, having a low income, and unstable employment were associated with an increased risk of T. vaginalis infection, with a pooled OR of 1.36 (95% CI: 1.10-1.66). This study has significant public health relevance for the prevention and control of trichomoniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.